Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 4, 2015, Pages 1079-1087

  Winter, Patrick M ^a   Pearce, John ^a   Chu, Zhengtao ^b   McPherson, Christopher M ^c   Takigiku, Ray ^d   Lee, Jing Huei ^c   Qi, Xiaoyang ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d Bexion Pharmaceuticals LLC   (United States)

Author keywords

cancer; contrast agent; glioblastoma multiforme; MRI

Indexed keywords

DIOLEYLPHOSPHATIDYLSERINE; GADOLINIUM; PENTETIC ACID; PHOSPHATIDYLSERINE; SAPOSIN C; SPHINGOLIPID ACTIVATOR PROTEIN; UNCLASSIFIED DRUG; 1-STREAROYL-2-ARACHIDONYL-SN-GLYCERO-3-PHOSPHATIDYLCHOLINE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; LIPOSOME; PHOSPHATIDYLCHOLINE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN TUMOR; CANCER CELL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEISURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR IMAGING; NUDE MOUSE; PATHOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; GLIOBLASTOMA; MICE; MICE, NUDE; MOLECULAR IMAGING; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLSERINES; TISSUE DISTRIBUTION; UNILAMELLAR LIPOSOMES;

EID: 84925268805     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24654     Document Type: Article

References (43)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C,. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14 (Suppl 5): v1-v49.
2. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O,. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 2006; 6: 1199-1209.
3. Pardridge WM,. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
4. Westphal M, Lamszus K,. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011; 12: 495-508.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
6. Wen PY, Kesari S,. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
7. Abu-Baker S, Chu Z, Stevens AM, Li J, Qi X,. Cytotoxicity and Selectivity in Skin Cancer by SapC-DOPS Nanovesicles. J Cancer Ther 2012; 3: 321-326.
8. Chu Z, Abu-Baker S, Palascak MB, Ahmad SA, Franco RS, Qi X,. Targeting and Cytotoxicity of SapC-DOPS Nanovesicles in Pancreatic Cancer. PLoS One 2013; 8: e75507.
9. Kaimal V, Chu Z, Mahller YY, et al. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol 2011; 13: 886-897.
10. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, Cripe TP,. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res 2009; 15: 5840-5851.
11. Unruh D, Turner K, Srinivasan R, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer 2014; 134: 9-20.
12. Wojton J, Chu Z, Mathsyaraja H, et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther 2013; 21: 1517-1525.
13. Darmoise A, Maschmeyer P, Winau F,. The immunological functions of saposins. Adv Immunol 2010; 105: 25-62.
14. Qi X, Chu Z,. Fusogenic domain and lysines in saposin C. Arch Biochem Biophys 2004; 424: 210-218.
15. Qi X, Qin W, Sun Y, Kondoh K, Grabowski GA,. Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions. J Biol Chem 1996; 271: 6874-6880.
16. Qi X, Grabowski GA,. Differential membrane interactions of saposins A and C: implications for the functional specificity. J Biol Chem 2001; 276: 27010-27017.
17. Vance JE, Steenbergen R,. Metabolism and functions of phosphatidylserine. Prog Lipid Res 2005; 44: 207-234.
18. Ran S, Thorpe PE,. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1479-1484.
19. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ,. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991; 51: 3062-3066.
20. Riedl S, Rinner B, Asslaber M, et al. In search of a novel target-phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim biophys Acta 2011; 1808: 2638-2645.
21. Balasubramanian K, Schroit AJ,. Aminophospholipid asymmetry: a matter of life and death. Annu Rev Physiol 2003; 65: 701-734.
22. Zhao D, Stafford JH, Zhou H, Thorpe PE,. Near-infrared optical imaging of exposed phosphatidylserine in a mouse glioma model. Transl Oncol 2011; 4: 355-364.
23. Yang L, Krefting I, Gorovets A, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 2012; 265: 248-253.
24. Deddens LH, Van Tilborg GA, Mulder WJ, De Vries HE, Dijkhuizen RM,. Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies. Cerebrovasc Dis 2012; 33: 392-402.
25. Hasan DM, Amans M, Tihan T, et al. Ferumoxytol-enhanced MRI to image inflammation within human brain arteriovenous malformations: a pilot investigation. Translational stroke research 2012; 3 (Suppl 1): 166-173.
26. McCullough BJ, Kolokythas O, Maki JH, Green DE,. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 2013; 37: 1476-1479.
27. Schwenk MH,. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 2010; 30: 70-79.
28. Pauleit D, Textor J, Bachmann R, et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222: 73-80.
29. Boles KS, Schmieder AH, Koch AW, et al. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010; 24: 4262-4270.
30. Jarzyna PA, Deddens LH, Kann BH, et al. Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging. Neoplasia 2012; 14: 964-973.
31. Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63: 5838-5843.
32. Winter PM, Schmieder AH, Caruthers SD, et al. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. Faseb J 2008; 22: 2758-2767.
33. Uppal R, Medarova Z, Farrar CT, Dai G, Moore A, Caravan P,. Molecular imaging of fibrin in a breast cancer xenograft mouse model. Invest Radiol 2012; 47: 553-558.
34. Blankenberg FG, Strauss HW,. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002; 16: 352-361.
35. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G,. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31: 887-919.
36. Yang TJ, Haimovitz-Friedman A, Verheij M,. Anticancer therapy and apoptosis imaging. Exp Oncol 2012; 34: 269-276.
37. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8: 2766-2774.
38. Kartachova MS, Valdes Olmos RA, et al. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun 2008; 29: 39-44.
39. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C,. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006; 47: 1813-1818.
40. van Tilborg GA, Mulder WJ, Chin PT, et al. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem 2006; 17: 865-868.
41. van Tilborg GA, Mulder WJ, Deckers N, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem 2006; 17: 741-749.
42. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L,. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 2004; 15: 1062-1067.
43. Krishnan AS, Neves AA, de Backer MM, et al. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology 2008; 246: 854-862.